Sphingosine-1-phosphate receptor 1-5 (S1PR1-5) (S1PR1-5)

The Sphingosine-1-phosphate receptor 1-5 (S1PR1-5) family consists of five G protein-coupled receptors (GPCRs) that mediate the signaling of the bioactive lipid sphingosine-1-phosphate (S1P) [1, 3]. These receptors are widely expressed and regulate critical physiological processes, including lymphocyte trafficking, vascular development, and endothelial barrier function [2, 4, 9]. S1PR1 is particularly vital for the egress of T and B cells from lymphoid organs into the circulation, a process that depends on the S1P concentration gradient between tissues and blood [11, 14]. Dysregulation of the S1P-S1PR axis is implicated in various autoimmune and inflammatory diseases, such as multiple sclerosis and ulcerative colitis, as well as in cancer progression and vascular disorders [5, 9, 16]. Therapeutic targeting of S1PRs has led to the development of S1P receptor modulators, which primarily act as functional antagonists [6, 15]. Upon binding, these drugs induce the internalization and subsequent degradation of the receptors (especially S1PR1), preventing lymphocytes from responding to the S1P gradient and thereby sequestering them in lymph nodes [14, 16]. This mechanism reduces the infiltration of autoreactive immune cells into the central nervous system or other inflamed tissues [11, 16]. While effective, these therapies are associated with specific safety concerns, such as transient bradycardia and macular edema, which are often related to the subtype selectivity of the modulator [6, 7, 16].

Other names

Sphingosine-1-phosphate receptorsS1P receptorsEDG receptorsEndothelial differentiation gene receptorsS1PRsEDG1-5

Functional antagonism via receptor internalization and degradation following initial agonism